Thermo Fisher (TMO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Ryskin from Bank of America Securities reiterated a Buy rating on the stock and has a $545.00 price target.
Michael Ryskin has given his Buy rating due to a combination of factors, primarily focusing on Thermo Fisher’s ability to manage and mitigate current macroeconomic challenges. Despite some reductions in the fiscal year 2025 guidance, such as a slight decrease in organic sales growth and adjusted EPS, the company has shown resilience by effectively offsetting impacts from tariffs and government policies. This ability to adapt and navigate through uncertainties is a key reason for the positive outlook.
Moreover, while there are lingering uncertainties related to macroeconomic changes and the long-term outlook of the tools market, Thermo Fisher’s management has demonstrated confidence in overcoming these challenges. The company’s strategic actions to counteract negative impacts and its potential for future growth, as reflected in the maintained price objective, support the Buy rating. Ryskin’s analysis suggests that Thermo Fisher is well-positioned to outperform its peers, even in a volatile market environment.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $570.00 price target.
TMO’s price has also changed moderately for the past six months – from $576.490 to $431.640, which is a -25.13% drop .